Short Interest in Ernexa Therapeutics Inc. (NASDAQ:ERNA) Drops By 49.8%

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a significant drop in short interest in July. As of July 15th, there was short interest totaling 14,740 shares, a drop of 49.8% from the June 30th total of 29,381 shares. Currently, 1.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,478,882 shares, the short-interest ratio is currently 0.0 days.

Hedge Funds Weigh In On Ernexa Therapeutics

An institutional investor recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 70.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Friday, July 17th. Zacks Research raised Ernexa Therapeutics to a “hold” rating in a report on Monday, May 11th. Brookline Capital Markets started coverage on Ernexa Therapeutics in a research report on Thursday, May 7th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Wall Street Zen upgraded Ernexa Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Ernexa Therapeutics currently has a consensus rating of “Hold” and an average target price of $30.00.

Ernexa Therapeutics Price Performance

Shares of ERNA stock traded down $0.23 during trading hours on Tuesday, hitting $3.69. The company had a trading volume of 7,566 shares, compared to its average volume of 943,616. The stock has a market capitalization of $4.32 million, a PE ratio of -0.14 and a beta of 2.50. The company’s fifty day moving average is $7.27 and its 200 day moving average is $10.46. Ernexa Therapeutics has a fifty-two week low of $3.18 and a fifty-two week high of $71.50.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its earnings results on Monday, May 11th. The company reported ($6.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00). Equities analysts forecast that Ernexa Therapeutics will post -18.02 earnings per share for the current year.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.